NASDAQ · CAN

Canaan Inc.. American

$0.26 +$0.02 (+9.09%) 1D Pre-market

Key Metrics

$176.23M
Market cap
P/E · TTM
Revenue · TTM
Net income
EPS · TTM
Dividend yield
Free cash flow −$295.83M
Beta · 1Y 3.91
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Jan 30 high, the share price fell 65%.

    Peak close $0.68 on Jan 30; trough close $0.24 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -65%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 8
    The stock moved +25.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 8
  • Feb 6
    The stock moved +17.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 6

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$176.23M
Enterprise value$147.70M
Shares outstanding744.8M
52-wk range$0.23 – $2.22
Avg volume · 20D12.5M
Net cash $28.53M
Book value / share$0.59
ExchangeNASDAQ
About Canaan Inc.. American
IPO dateNov 21, 2019
Employees399

Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC — · —

Financial Health

Current ratio3.31
Quick ratio1.93
Debt / equity0.12
Debt / EBITDA
Net cash $28.53M
Working capital$302.20M

Cash Flow · TTM

Operating CF −$271.22M
Capex −$24.61M
Free cash flow −$295.83M
Buybacks $5.00M
Dividends paid
Shareholder yield 2.8%

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-12-31 · computed by TickerWolf from SEC filings